Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-399-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
Cross-referenceopen allclose all
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- no
- Limit test:
- no
- Species:
- mouse
- Strain:
- CD-1
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- VEHICLE
- Concentration in vehicle: no data - Details on mating procedure:
- no further specified
- Duration of treatment / exposure:
- day 6 - 15 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- sacrifice at day 17 of gestation
- Dose / conc.:
- 0.2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 600 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 20
- Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- -Clinical observations:
Animals were observed daily for signs of toxicity and were weighed regularly throughout gestation.
- Organs examined at necropsy (macroscopic and microscopic):
All animals, including those that died during the study, were dissected and examined for macroscopic changes immediately after sacrifice. - Ovaries and uterine content:
- Uteri were dissected and the contents examined to determine the numbers of implantations, viable young and embryonic deaths.
- Fetal examinations:
- Fetuses were examined for visceral anomalies, or dissected and examined followed by clearing, alizarin staining and skeletal examination.
- Statistics:
- Wilcoxon test
- Description (incidence):
- 300 mg/kg: mortality 1/20
600 mg/kg: mortality 4/20 - Dose descriptor:
- NOAEL
- Remarks:
- maternal toxicity
- Effect level:
- ca. 2 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: no effects observed
- Dose descriptor:
- LOAEL
- Remarks:
- maternal toxicity
- Effect level:
- ca. 300 mg/kg bw/day (actual dose received)
- Basis for effect level:
- mortality
- Description (incidence and severity):
- <= 300 mg/kg: no adverse effects on foetal morphogenesis
600 mg/kg: total resorption and/or increased incidence of litter loss - Key result
- Dose descriptor:
- NOAEL
- Remarks:
- teratogenicity
- Effect level:
- ca. 300 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: resorption
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Lowest effective dose / conc.:
- 300 mg/kg bw/day
- Treatment related:
- yes
- Conclusions:
- Under the present test conditions the following effect levels were established:
NOAEL maternal toxicity= 2 mg/kg bw
NOAEL teratogenicity= 300 mg/kg bw
LOAEL maternal toxicity = 300 mg/kg bw - Executive summary:
The IUCLID dataset of C12-Alkylsulfate (CAS 151-21-3) in the OECD SIDS Initial Assessment Profile on Sodium dodecyl sulfate (SDS) describes the following Klimisch 2 study.
Sodium dodecyl sulphate was administered to 20 female CD-1 mice per dose group.
The mice were dosed by gavage with water as vehicle once daily at 0, 0.2, 2, 300 or 600 mg /kg bw/d from days 6- 15 of gestation.
The animals were observed daily for signs of toxicity and were weighed regularly throughout gestation and were sacrificed at day 17 of gestation.
All animals, including those that died during the study, were dissected and examined for macroscopic changes immediately after sacrifice.
Uteri were dissected and the contents examined to determine the numbers of implantations, viable young and embryonic deaths.
Fetuses were examined for visceral anomalies, or dissected and examined followed by clearing, alizarin staining and skeletal examination.
Viable young were weighed and examined for external abnormalities.
Maternal data:
300 mg/kg: mortality 1/20
600 mg/kg: mortality 4/20
Offspring:
<= 300 mg/kg: no adverse effects on foetal morphogenesis
600 mg/kg: total resorption and/or increased incidence of litter loss
The following effect levels were established:
NOAEL maternal toxicity= 2 mg/kg bw
NOAEL teratogenicity= 300 mg/kg bw
LOAEL maternal toxicity = 300 mg/kg bw
Reference:
-Palmer AK, Readshaw MA & Neuff AM (1975) Assessment of the teratogenic potential of surfactants. Part I - LAS, AS and CLD. Toxicology 3, 91 - 106
-Palmer AK, Readshaw MA & Neuff AM (1975) Assessment of the teratogenic potential of surfactants. Part II - AOS. Toxicology 3, 107 – 113
Observation |
Dose (mg/kg bw) |
||||
0 |
0.2 |
2 |
300 |
600 |
|
mated |
20 |
20 |
20 |
20 |
20 |
died |
0 |
0 |
0 |
1 |
4 |
non-pregnant |
2 |
2 |
3 |
4 |
2 |
total litter loss |
0 |
2 |
2 |
2 |
4 |
With viable young |
18 |
16 |
15 |
13 |
10 |
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rat
- Strain:
- other: CD
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
-Total volume applied: no data
VEHICLE
- Concentration in vehicle: no data - Details on mating procedure:
- no further specified
- Duration of treatment / exposure:
- day 6 - 15 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- sacrifice at day 20 of gestation
- Dose / conc.:
- 0.2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 600 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 20
- Control animals:
- yes, concurrent vehicle
- Maternal examinations:
- -Clinical observations:
Animals were observed daily for signs of toxicity and were weighed regularly throughout gestation.
- Organs examined at necropsy (macroscopic and microscopic):
All animals, including those that died during the study, were dissected and examined for macroscopic changes immediately after sacrifice. - Ovaries and uterine content:
- Uteri were dissected and the contents examined to determine the numbers of implantations, viable young and embryonic deaths. Ovaries were examined and the number of corpora lutea were counted.
- Fetal examinations:
- Viable young were weighed and examined for external abnormalities.
Fetuses were examined for visceral anomalies, or dissected and examined followed by clearing, alizarin staining and skeletal examination. - Statistics:
- Wilcoxon test
- Description (incidence and severity):
- >= 300 mg/kg: slight to moderate toxicity (anorexia, weight loss, cachexia, abortion)
- Description (incidence):
- 600 mg/kg: mortality 3/20
- Description (incidence and severity):
- >= 300 mg/kg: slight to moderate toxicity (abortion)
- Dose descriptor:
- NOAEL
- Remarks:
- maternal toxicity
- Effect level:
- ca. 2 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: no effects observed
- Dose descriptor:
- LOAEL
- Remarks:
- maternal toxicity
- Effect level:
- ca. 300 mg/kg bw/day (actual dose received)
- Basis for effect level:
- number of abortions
- Details on embryotoxic / teratogenic effects:
- 600 mg/kg: no adverse effects
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- teratogenicity
- Effect level:
- ca. 600 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- external malformations
- skeletal malformations
- visceral malformations
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Lowest effective dose / conc.:
- 600 mg/kg bw/day
- Treatment related:
- yes
- Conclusions:
- Under the present test conditions the following effect levels were established:
NOAEL maternal toxicity= 2 mg/kg bw
NOAEL teratogenicity= 600 mg/kg bw
LOAEL maternal toxicity = 300 mg/kg bw - Executive summary:
The IUCLID dataset of C12-Alkylsulfate (CAS 151-21-3) in the OECD SIDS Initial Assessment Profile on Sodium dodecyl sulfate (SDS) describes the following Klimisch 2 study.
Sodium dodecyl sulphate was administered to 20 female CD rats per dose group.
The rats were dosed by gavage with water as vehicle once daily at 0, 0.2, 2, 300 or 600 mg /kg bw/d from days 6- 15 of gestation.
The animals were observed daily for signs of toxicity and were weighed regularly throughout gestation and were sacrificed at day 20 of gestation.
All animals, including those that died during the study, were dissected and examined for macroscopic changes immediately after sacrifice.
Uteri were dissected and the contents examined to determine the numbers of implantations, viable young and embryonic deaths.
Ovaries were examined and the number of corpora lutea were counted.
Fetuses were examined for visceral anomalies, or dissected and examined followed by clearing, alizarin staining and skeletal examination.
Viable young were weighed and examined for external abnormalities.
Maternal data:
>= 300 mg/kg: slight to moderate toxicity (anorexia, weight loss, cachexia, abortion)
600 mg/kg: mortality 3/20
Offspring:
600 mg/kg: no adverse effects
The following effect levels were established:
NOAEL maternal toxicity= 2 mg/kg bw
NOAEL teratogenicity= 600 mg/kg bw
LOAEL maternal toxicity = 300 mg/kg bw
Reference:
-Palmer AK, Readshaw MA & Neuff AM (1975) Assessment of the teratogenic potential of surfactants. Part I - LAS, AS and CLD. Toxicology 3, 91 - 106
-Palmer AK, Readshaw MA & Neuff AM (1975) Assessment of the teratogenic potential of surfactants. Part II - AOS. Toxicology 3, 107 - 113
Observation |
Dose (mg/kg bw) |
||||
0 |
0.2 |
2 |
300 |
600 |
|
mated |
20 |
20 |
20 |
20 |
20 |
died |
0 |
0 |
0 |
0 |
3 |
non-pregnant |
3 |
1 |
2 |
1 |
0 |
total litter loss |
0 |
0 |
0 |
0 |
0 |
With viable young |
17 |
19 |
18 |
19 |
17 |
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1975
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Principles of method if other than guideline:
- 13 animals/group
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rabbit
- Strain:
- New Zealand White
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- VEHICLE
- Concentration in vehicle: no data - Duration of treatment / exposure:
- day 6 - 18 of gestation
- Frequency of treatment:
- daily
- Duration of test:
- sacrifice at day 29 of gestation
- Dose / conc.:
- 0.2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 2 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 600 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 13
- Control animals:
- yes, concurrent vehicle
- Description (incidence and severity):
- >= 300 mg/kg: diarrhoea, anorexia, cachexia,
- Description (incidence):
- 300 mg/kg: mortality 1/13
600 mg/kg: mortality 11/13 - Description (incidence and severity):
- >= 300 mg/kg: weight loss
- Details on maternal toxic effects:
- >= 300 mg/kg: foetal loss
- Dose descriptor:
- NOAEL
- Remarks:
- maternal toxicity
- Effect level:
- ca. 2 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: no effects observed
- Dose descriptor:
- LOAEL
- Remarks:
- maternal toxicity
- Effect level:
- ca. 300 mg/kg bw/day (actual dose received)
- Basis for effect level:
- body weight and weight gain
- mortality
- Details on embryotoxic / teratogenic effects:
- <= 300 mg/kg: no adverse effects on foetal morphogenesis
600 mg/kg: abortion, total resorption and/or increased incidence of litter loss - Key result
- Dose descriptor:
- NOAEL
- Remarks:
- teratogenicity
- Effect level:
- ca. 300 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- external malformations
- skeletal malformations
- visceral malformations
- Key result
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- other: not specified
- Key result
- Developmental effects observed:
- no
- Lowest effective dose / conc.:
- 600 mg/kg bw/day
- Treatment related:
- yes
- Conclusions:
- Under the present test conditions the following effect levels were established:
NOAEL maternal toxicity= 2 mg/kg bw
NOAEL teratogenicity= 300 mg/kg bw
LOAEL maternal toxicity = 300 mg/kg bw - Executive summary:
The IUCLID dataset of C12-Alkylsulfate (CAS 151-21-3) in the OECD SIDS Initial Assessment Profile on Sodium dodecyl sulfate (SDS) describes the following Klimisch 2 study.
Sodium dodecyl sulphate was administered to 13 female New Zealand White rabbits per dose group.
The rabbits were dosed by gavage with water as vehicle once daily at 0, 0.2, 2, 300 or 600 mg /kg bw/d from days 6- 18 of gestation.
The animals were observed daily for signs of toxicity and were weighed regularly throughout gestation and were sacrificed at day 29 of gestation.
All animals, including those that died during the study, were dissected and examined for macroscopic changes immediately after sacrifice.
Uteri were dissected and the contents examined to determine the numbers of implantations, viable young and embryonic deaths.
Ovaries were examined and the number of corpora lutea were counted.
Fetuses then were dissected and examined for abnormalities of internal organs, sex determination, and clearing, alizarin staining and skeletal examination.
Viable young were weighed and examined for external abnormalities.
Maternal data:
300 mg/kg: mortality 1/13
>= 300 mg/kg: diarrhoea, anorexia, weight loss, cachexia, foetal loss
600 mg/kg: mortality 11/13
Offspring:
<= 300 mg/kg: no adverse effects on foetal morphogenesis
600 mg/kg: abortion, total resorption and/or increased incidence of litter loss
The following effect levels were established:
NOAEL maternal toxicity= 2 mg/kg bw
NOAEL teratogenicity= 300 mg/kg bw
LOAEL maternal toxicity = 300 mg/kg bw
Reference:
-Palmer AK, Readshaw MA & Neuff AM (1975) Assessment of the teratogenic potential of surfactants. Part I - LAS, AS and CLD. Toxicology 3, 91 - 106
-Palmer AK, Readshaw MA & Neuff AM (1975) Assessment of the teratogenic potential of surfactants. Part II - AOS. Toxicology 3, 107 – 113
Observation |
Dose (mg/kg bw) |
||||
0 |
0.2 |
2 |
300 |
600 |
|
mated |
13 |
13 |
13 |
13 |
13 |
died |
2 |
0 |
1* |
1 |
11 |
non-pregnant |
1 |
1 |
2 |
1 |
0 |
total litter loss |
0 |
1 |
0 |
2 |
0 |
With viable young |
10 |
11 |
10 |
9 |
2 |
* intubation error
Reference
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1976
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Principles of method if other than guideline:
- 15 animals/group (10 for dissection, 5 for natural parturition)
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 16 - 18 weeks - Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Details on mating procedure:
- Virgin female rats were taken at random from a stock cage and recaged in groups of 3 with each of 15 virgin male rats of the same age and from the same colony. The dropping trays were examined each morning thereafter for ejected vaginal plugs, and when these were found the female rats were removed and individually examined for evidence of mating. Confirmation of mating was established by microscopically examination of the vaginal mucus for the presence of spermatozoa.
- Duration of treatment / exposure:
- days 6 - 15 of gestation
- Frequency of treatment:
- once daily
- Duration of test:
- termination on day 21 of gestation or up to weaning day 21
- Dose / conc.:
- 63 mg/kg bw/day (actual dose received)
- Remarks:
- test substance
- Dose / conc.:
- 125 mg/kg bw/day (actual dose received)
- Remarks:
- test substance
- Dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- Remarks:
- test substance
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- Remarks:
- test substance
- No. of animals per sex per dose:
- 15 rats per dose group (10 for dissection, 5 for natural parturition)
- Control animals:
- yes
- Maternal examinations:
- -body weight: daily
-maternal food intake: daily - Ovaries and uterine content:
- -mean gravid uterus weight & mean weight of uterine tissue; intrauterine mortality; mean response per pregnancy; mean foetal body weight, crown rump distance and mean placental weight; % incidence of external and gross visceral observations of foetuses; incidence of skeletal variants/anomalies of foetuses; incidence and distribution of other anomalies;
- Fetal examinations:
- post-partum mortalities; mean body weight of pups (at birth and on days 7, 14 and 21); weaned of born; incidence of external and gross visceral variations of pups; incidence of skeletal variations of pups
- Description (incidence and severity):
- All animals at 500 mg/kg had diarrhoea, which continued until cessation of treatment. With successive treatments the passage of the cannula down the oesophagus became more difficult suggesting a dryness of the membranes, and the demeanour of the animals became more aggressive. Between the 4th and 8th dose 4 of the animals of this group died and 1 was killed because of its condition. A further animal aborted on the 14th day of gestation having received 9 treatments. All the animals which died showed evidence of gastrointestinal irritation and diffuse haemorrhage of the stomach. In 3 instances there was also congestion of the lungs.
- Description (incidence):
- Between the 4th and 8th dose 4 of the animals of the 500 mg/kg dose group died and 1 was killed because of its condition.
- Description (incidence and severity):
- Treatment with 500 mg/kg induced a significant (p = < 0.05) reduction in maternal body weight gain during the period of treatment.
- Description (incidence and severity):
- Rats treated with 500 mg/kg consumed significantly (p=<0.05) less food than controls.
- Description (incidence and severity):
- Treatment did not adversely affect the pre- or post-implantation loss.
- Description (incidence and severity):
- Intrauterine mortality: No significant differences between treatment and control
- Dose descriptor:
- NOAEL
- Remarks:
- maternal toxicity
- Effect level:
- ca. 250 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: no effects observed
- Dose descriptor:
- LOAEL
- Remarks:
- maternal toxicity
- Effect level:
- ca. 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- gross pathology
- other: placental weight
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- teratogenicity
- Effect level:
- ca. 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- external malformations
- skeletal malformations
- visceral malformations
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Lowest effective dose / conc.:
- 500 mg/kg bw/day
- Treatment related:
- yes
- Conclusions:
- Under the present test conditions the following effect levels were established:
NOAEL maternal toxicity= 250 mg/kg bw
NOAEL teratogenicity= 500 mg/kg bw
LOAEL maternal toxicity = 500 mg/kg bw - Executive summary:
The IUCLID dataset of C12-Alkylsulfate (CAS 151-21-3) in the OECD SIDS Initial Assessment Profile on Sodium dodecyl sulfate (SDS) describes the following Klimisch 2 study.
Sodium dodecyl sulphate was administered to 15 female Wistar rats per dose group (10 for dissection, 5 for natural parturition). The rats were dosed by gavage once daily at 0, 63, 125, 250 or 500 mg test substance/kg bw/d from days 6- 15 of gestation.
The following observations were performed:
-body weight: daily
-maternal food intake: daily
-mean gravid uterus weight & mean weight of uterine tissue; intrauterine mortality; mean response per pregnancy; mean foetal body weight, crown rump distance and mean placental weight; % incidence of external and gross visceral observations of foetuses; incidence of skeletal variants/anomalies of foetuses; incidence and distribution of other anomalies; post-partum mortalities; mean body weight of pups (at birth and on days 7, 14 and 21); weaned of born; incidence of external and gross visceral variations of pups; incidence of skeletal variations of pups
All maternal animals at 500 mg/kg had diarrhoea, which continued until cessation of treatment. With successive treatments the passage of the cannula down the oesophagus became more difficult suggesting a dryness of the membranes, and the demeanour of the animals became more aggressive. Between the 4th and 8th dose 4 of the animals of this group died and 1 was killed because of its condition. A further animal aborted on the 14th day of gestation having received 9 treatments. All the animals which died showed evidence of gastrointestinal irritation and diffuse haemorrhage of the stomach. In 3 instances there was also congestion of the lungs.
Treatment with 500 mg/kg induced a significant (p = < 0.05) reduction in maternal body weight gain during the period of treatment.
Rats treated with 500 mg/kg consumed significantly (p=<0.05) less food than controls.
No significant differences in intrauterine mortality were observed between treatment and control animals.
Treatment did not adversely affect the pre- or post-implantation loss.
The mean placental weight for male and female foetuses combined and considered separately were significantly lower in animals fed 500 mg/kg (p= 0.05).
No significant differences in incidence of gross variants/anomalies and skeletal anomalies between treatment groups and control group in the offspring.
Malformations were found in 3 foetuses from dams treated with 500 mg/kg: protruding tongue, gross oedema and shortening of the pubic bone; agenesis of eyelids and cleft palate; unossified metatarsus and claw in left hind foot. The foetuses were all taken from separate pregnancies. A single live foetus with a malformation was also found after treatment with 250 mg/kg (hermi-centric lumbar centra with asymmetry and reduced ossification of the 6th lumbar arch and scoliosis) and 63 mg/kg (unossified and dumbbell shaped thoracic centrae associated with branched ribs).
In the rats allocated to natural parturition, no significant differences in post-partum mortalities and incidence of skeletal defects in rat pups were observed between treatment and controls.
The following effect levels were established:
NOAEL maternal toxicity= 250 mg/kg bw
NOAEL teratogenicity= 500 mg/kg bw
LOAEL maternal toxicity = 500 mg/kg bw
Reference: Unilever Research (1976) Mutagenicity and teratology of alternative surfactants. IV. Teratology of sodium lauryl sulphate: oral administration in the rat (Unpublished Report No. PCW 76 1593). Unilever Research, Colworth/Welwyn. 70 pp.
Maternal data
General health:
All animals at 500 mg/kg had diarrhoea, which continued until cessation of treatment. With successive treatments the passage of the cannula down the oesophagus became more difficult suggesting a dryness of the membranes, and the demeanour of the animals became more aggressive. Between the 4th and 8th dose 4 of the animals of this group died and 1 was killed because of its condition. A further animal aborted on the 14th day of gestation having received 9 treatments. All the animals which died showed evidence of gastrointestinal irritation and diffuse haemorrhage of the stomach. In 3 instances there was also congestion of the lungs.
Mean maternal body weight gain:
Treatment with 500 mg/kg induced a significant (p = < 0.05) reduction in maternal body weight gain during the period of treatment.
Food consumption:
Rats treated with 500 mg/kg consumed significantly (p=<0.05) less food than controls
Intrauterine mortality:
No significant differences between treatment and control
Mean response per pregnancy:
Treatment did not adversely affect the pre- or post-implantation loss
Offspring:
Foetal and placental size:
The mean placental weight for male and female foetuses combined and considered separately were significantly lower in animals fed 500 mg/kg (p= 0.05).
Incidence of gross variants/anomalies:
No significant differences between treatment groups and control group
Incidence of skeletal anomalies:
No significant differences between treatment groups and control group
Incidence of foetal variations, minor anomalies and major malformations:
Malformations were found in 3 foetuses from dams treated with 500 mg/kg - protruding tongue, gross oedema and shortening of the pubic bone; agenesis of eyelids and cleft palate; unossified metatarsus and claw in left hind foot. The foetuses were all taken from separate pregnancies. A single live foetus with a malformation was also found after treatment with 250 mg/kg (hermi-centric lumbar centra with asymmetry and reduced ossification of the 6th lumbar arch and scoliosis) and 63 mg/kg (unossified and dumbbell shaped thoracic centrae associated with branched ribs)
Rats allocated to natural parturition:
Post-partum mortalities:
No significant differences between treatment and controls.
Incidence of skeletal defects in rat pups:
No significant differences between treatment groups and control group.
Data source
Materials and methods
Test material
- Reference substance name:
- Sulfuric acid, C16-C18 (even numbered) alkyl esters, sodium salts and C16-18 (even numbered) alcohols
- EC Number:
- 944-399-8
- Cas Number:
- not yet assigned
- Molecular formula:
- see information in structural formula
- IUPAC Name:
- Sulfuric acid, C16-C18 (even numbered) alkyl esters, sodium salts and C16-18 (even numbered) alcohols
Constituent 1
Results and discussion
Applicant's summary and conclusion
- Conclusions:
- When the NOAEL of the target substance was calculated by concentration addition based on the general equation as presented in the CLP regulation on mixtures (2008) from NOAEL values of the components (C16 and C18 LCOH; C12 AS as worst case), this resulted in an oral reproductive NOAEL of 1200 mg/kg bw in rats. It can therefore be concluded that the oral reproductive NOAEL of the registered substance is 1200 mg/kg bw.
- Executive summary:
When the NOAEL of the target substance was calculated by concentration addition based on the general equation as presented in the CLP regulation on mixtures (2008) from NOAEL values of the components (C16 and C18 LCOH; C12 AS as worst case), this resulted in an oral reproductive NOAEL of 1200 mg/kg bw in rats. It can therefore be concluded that the oral reproductive NOAEL of the registered substance is 1200 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.